[Pharmacokinetic mechanisms of resistance to anticancer medications].
Besides the cellular mechanisms of resistance, which can be described in terms of molecular alterations, the lack of sensitivity of a tumour to a drug may result from an inadequacy between the pharmacokinetics of the drug and the kinetics of the tumour cells. Dose and duration of infusion of a drug may govern its activity; the drugs exhibiting a short half-life in plasma and a marked phase-dependence in their mechanism of action have to be administered as continuous infusions. The existence of sanctuary compartments within the body, which are protected by barriers such as the blood-brain barrier, may also contribute to the failure of the molecules unable to cross these barriers. Finally, the tumour cell kinetics may unfavour the general activity of drugs: this is the case of slowly growing tumours, which contain an important proportion of GO cells. The optimisation of the mode of administration of a drug is a requisite for the expression of its activity.